Urologix (ULGX) 10-K 19 Sep 14 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Jun. 30, 2014	Sep. 01, 2014	Dec. 31, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	30-Jun-14	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'UROLOGIX INC	'	'
Entity Central Index Key	'0000882873	'	'
Current Fiscal Year End Date	'--06-30	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	21,655,906	'
Entity Public Float	'	'	$3,574,987
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'

Balance_Sheets

Balance Sheets (USD $)	Jun. 30, 2014	Jun. 30, 2013
Current Assets:	'	'
Cash	$718,000	$2,290,000
Accounts receivable, net of allowance of $76 and $79, respectively	1,502,000	2,132,000
Inventories	1,397,000	1,571,000
Prepaids and other current assets	63,000	128,000
Total current assets	3,680,000	6,121,000
Property and equipment:	'	'
Property and equipment	12,162,000	12,165,000
Less accumulated depreciation	-11,691,000	-11,430,000
Property and equipment, net	471,000	735,000
Other intangible assets, net	1,370,000	1,587,000
Goodwill	'	3,036,000
Long-term inventories	141,000	1,043,000
Other assets	5,000	5,000
Total assets	5,667,000	12,527,000
Current liabilities:	'	'
Accounts payable	892,000	628,000
Accrued compensation	487,000	721,000
Deferred income	6,000	5,000
Short-term deferred acquisition payment	1,339,000	681,000
Current portion of long-term debt	747,000	'
Interest payable	322,000	'
Other accrued expenses	499,000	602,000
Total current liabilities	4,292,000	2,637,000
Deferred tax liability	'	36,000
Long-term deferred acquisition payment	3,730,000	4,026,000
Long-term debt	4,586,000	5,333,000
Other accrued expenses	36,000	75,000
Total liabilities	12,644,000	12,107,000
Commitments and Contingencies (Note 13)	'	'
SHAREHOLDERS' EQUITY/(DEFICIT):	'	'
Common stock, $.01 par value, 30,000 and 25,000 shares authorized; 21,291 and 20,909 shares issued; and 20,945 and 20,795 shares outstanding	209,000	208,000
Additional paid-in capital	119,440,000	119,230,000
Accumulated deficit	-126,626,000	-119,018,000
Total shareholders' equity/(deficit)	-6,977,000	420,000
Total liabilities and shareholders' equity/(deficit)	$5,667,000	$12,527,000

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, except Share data, unless otherwise specified
Balance Sheets [Abstract]	'	'
Accounts receivable, allowances (in dollars)	$76	$79
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	30,000,000	25,000,000
Common stock, shares issued (in shares)	21,291,000	20,909,000
Common stock, shares outstanding (in shares)	20,945,000	20,795,000

Statements_Of_Operations

Statements Of Operations (USD $)	12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Statements Of Operations [Abstract]	'	'
SALES	$14,235,000	$16,590,000
COST OF GOODS SOLD	8,142,000	8,407,000
Gross profit	6,093,000	8,183,000
COSTS AND EXPENSES	'	'
Sales and marketing	5,850,000	7,719,000
General and administrative	2,299,000	2,515,000
Research and development	1,625,000	2,269,000
Change in value of acquisition consideration	-105,000	-447,000
Goodwill Impairment	3,036,000	0
Gain on demutualization	'	-321,000
Medical device tax	223,000	106,000
Amortization of identifiable intangible assets	95,000	104,000
Impairment of identifiable intangible assets	'	160,000
Total costs and expenses	13,023,000	12,105,000
OPERATING LOSS	-6,930,000	-3,922,000
INTEREST INCOME/EXPENSE	-693,000	-555,000
GAIN ON DEBT EXTINGUISHMENT	'	206,000
FOREIGN CURRENCY EXCHANGE LOSS	-1,000	-7,000
LOSS BEFORE INCOME TAXES	-7,624,000	-4,278,000
INCOME TAX (BENEFIT)/EXPENSE	-16,000	14,000
NET LOSS	($7,608,000)	($4,292,000)
NET LOSS PER COMMON SHARE - BASIC	($0.36)	($0.21)
NET LOSS PER COMMON SHARE - DILUTED	($0.36)	($0.21)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC	21,219	20,703
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED	21,219	20,703

Statements_Of_Shareholders_Equ

Statements Of Shareholders' Equity/(Deficit) (USD $)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
In Thousands, except Share data
Balance at Jun. 30, 2012	$147	$115,205	($114,726)	$626
Balance, shares at Jun. 30, 2012	14,719,000	'	'	'
Net loss	'	'	-4,292	-4,292
Stock options exercised	'	15	'	15
Stock options exercised, shares	20,000	'	'	'
Vesting of restricted stock	1	-1	'	'
Vesting of restricted stock, shares	76,000	'	'	'
Stock-based compensation	'	257	'	257
Issuance of common stock, value	60	3,754	'	3,814
Issuance of common stock, shares	5,980,000	'	'	'
Balance at Jun. 30, 2013	208	119,230	-119,018	420
Balance, shares at Jun. 30, 2013	20,795,000	'	'	20,795,000
Net loss	'	'	-7,608	-7,608
Stock options exercised, shares	'	'	'	0
Vesting of restricted stock	1	-1	'	'
Vesting of restricted stock, shares	110,000	'	'	'
Stock-based compensation	40	211	'	211
Balance at Jun. 30, 2014	$209	$119,440	($126,626)	($6,977)
Balance, shares at Jun. 30, 2014	20,945,000	'	'	20,945,000

Statements_Of_Cash_Flows

Statements Of Cash Flows (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
OPERATING ACTIVITIES	'	'
Net loss	($7,608,000)	($4,292,000)
Adjustments to reconcile net loss to net cash used for operating activities:	'	'
Depreciation and amortization	587,000	674,000
Impairment of identifiable intangible assets	'	434,000
Impairment of goodwill	3,036,000	0
Employee stock-based compensation expense	211,000	257,000
Provision for bad debts	10,000	-23,000
Prostiva inventory reserve	739,000	'
Loss on disposal of assets	6,000	7,000
Accretion expense on deferred acquisition payments	467,000	544,000
Net adjustment to acquisition consideration	-105,000	-447,000
Gain on debt extinguishment	'	-206,000
Deferred income taxes	-36,000	1,000
Change in operating assets and liabilities:	'	'
Accounts receivable	620,000	23,000
Inventories	267,000	-626,000
Prepaids and other assets	65,000	162,000
Accounts payable	264,000	1,760,000
Accrued expenses and deferred income	-375,000	-227,000
Interest payable	322,000	'
Net cash used for operating activities	-1,530,000	-1,959,000
INVESTING ACTIVITIES	'	'
Purchases of property and equipment	-32,000	-79,000
Acquisition of business	'	-1,368,000
Purchases of intellectual property	-10,000	-32,000
Net cash used for investing activities	-42,000	-1,479,000
FINANCING ACTIVITIES	'	'
Proceeds from stock option exercises	'	15,000
Issuance of common stock	'	3,814,000
Net cash provided by financing activities	'	3,829,000
NET INCREASE/(DECREASE) IN CASH	-1,572,000	391,000
CASH	'	'
Beginning of year	2,290,000	1,899,000
End of year	718,000	2,290,000
Supplemental cash-flow information	'	'
Income taxes paid during the period	27,000	17,000
Net carrying amount of inventory transferred to property and equipment	70,000	202,000
Deferred acquisition payment and accounts payable transferred to long-term debt	'	$5,333,000

Nature_Of_Business

Nature Of Business	12 Months Ended
	Jun. 30, 2014
Nature Of Business [Abstract]	'
Nature Of Business	'
	1.Nature of Business
	Description of Operating Activities
	Urologix, Inc. (the “Company,” “Urologix,” “we”) consists of one reportable segment.  Urologix is based in Minneapolis and develops, manufactures and markets minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH).  Urologix' Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort.  The Cooled ThermoTherapy™ product line includes the CoolWave® and Targis® Control Units and the CTC Advance® catheter.  The Prostiva® RF Therapy System licensed from Medtronic, Inc., delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms.  Both of these products provide safe, effective and lasting relief of the symptoms and obstruction due to BPH.

Significant_Accounting_Policie

Significant Accounting Policies

12 Months Ended

Jun. 30, 2014

Significant Accounting Policies [Abstract]

'

Significant Accounting Policies

'

2.Significant Accounting Policies

Revenue Recognition

We recognize revenue from the sale of Cooled ThermoTherapy control units upon delivery to the customer, which include urologists, urology practices, mobile units, clinics and hospitals. We recognize revenue from the sale of Prostiva generators upon shipment to the customer. Revenue is recognized in accordance with generally accepted accounting principles as outlined in Accounting Standards Codification (“ASC”) 605-10-S99, Revenue Recognition, which requires that four basic criteria be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) product delivery has occurred or services have been rendered.  The Company recognizes revenue as products are shipped based on FOB shipping point terms when title passes to customers.  In addition to our sales of Cooled ThermoTherapy control units and Prostiva generators, we place our control units and generators with customers free of charge under a variety of programs for both evaluation and long-term use, and also provide access to Cooled ThermoTherapy and Prostiva RF Therapy treatments via our Urologix mobile service. We retain title to the control units and generators placed with our customers for evaluation and longer-term use. These programs, as well as our Urologix mobile service, are designed to expand access to our technology, and thus expand the market for our single-use treatment catheters and Prostiva handpieces. The free use of our Cooled ThermoTherapy control units and Prostiva generators are bundled with the sale of single-use treatment catheters or Prostiva handpieces and scopes, respectively, and are considered a single unit of accounting. Revenue from the bundled sales is recognized when the single-use treatment catheters or handpieces and scopes are shipped to our customers. Revenue from our mobile service is recognized upon treatment of the patient. Revenue for extended warranty service contracts is deferred and recognized over the contract period on a straight-line basis. We record a provision for estimated sales returns on product sales in the same period as the related revenue is recorded. The provision for estimated sales returns is based on historical sales returns, analysis of credit memo data and specific customer-based circumstances. Should actual sales returns differ from our estimates, revisions to the sales return reserve would be required. Sales and use taxes are reported on a net basis, excluding them from revenue.

Allowance for Doubtful Accounts

We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  We consider factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay when determining the adequacy of the allowance.  Invoices are generally due 30 days after presentation.  Accounts receivable over 30 days are considered past due.  Accounts receivable are written-off after management determines they are uncollectible.

Bad debt and sales returns provisions and accounts receivable write-offs for the years ended June 30, 2014 and  2013 were as follows (in thousands):

Beginning

Ending

Years Ended

Balance

Provisions

Write-offs

Balance

30-Jun-14

$

79

$

10

$

-13

$

76

30-Jun-13

83

38

-42

79

Inventories

Inventories are stated at the lower of cost or market on a first-in, first-out (FIFO) basis and consist of:

(in thousands)

30-Jun-14

30-Jun-13

Raw materials

$

685

$

734

Work-in-process

127

112

Finished goods

726

1,768

Total inventories

$

1,538

$

2,614

We took a non-cash write-down of our Prostiva capital equipment inventory of approximately $739,000, which included approximately $504,000 of finished goods inventory acquired as part of the September 6, 2011 Prostiva acquisition in the quarter ended March 31, 2014.  This inventory continues to be reserved for as of June 30, 2014.  The write-down of the Prostiva capital equipment inventory was due to low volume sales of the Prostiva generators and scopes, as well as the implementations of the recent restructurings that occurred in January and April of fiscal year 2014 as a result of our change in sales strategy.  In addition, as of June 30, 2014 and 2013, $141,000 and $1,043,000, respectively, of the above finished goods balance represents long-term inventories that the Company does not expect to sell within the next 12 months, however, they are not considered excess or obsolete.

Valuation of Long-Lived Assets and Goodwill

We assess the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An asset or asset group is considered impaired if its carrying amount exceeds the undiscounted future net cash flows the asset or asset group is expected to generate. If an asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. If estimated fair value is less than the book value, the asset is written down to the estimated fair value and an impairment loss is recognized.

Goodwill is tested for impairment annually on April 30th or more frequently if changes in circumstance or the occurrence of events suggests an impairment may exist. To determine if there is goodwill impairment, the fair value of the reporting unit is compared to its carrying amount.  If the fair value of a reporting unit is less than its carrying value, or if there is a shareholders’ deficit, an impairment loss is recorded to the extent that the fair value of the goodwill is less than the carrying value of the goodwill. The test for impairment requires us to make several estimates about fair value, most of which are based on projected future cash flows.

Considerable management judgment is necessary in estimating future cash flows and other factors affecting the valuation of long-lived assets and goodwill, including the operating and macroeconomic factors that may affect them. We use historical financial information, internal plans and projections and industry information in making such estimates.

As a result of the delisting of our common stock from the NASDAQ exchange on June 7, 2013 and the continued decline of our stock price, we tested our long-lived assets and goodwill for impairment as of June 30, 2013.  Based on this impairment testing it was determined that our intangible assets acquired as part of the Prostiva acquisition were impaired.  As a result, we recorded an impairment charge of $274,000 on our developed technology asset which was recorded in cost of goods sold, a $95,000 impairment charge on our customer base asset and a $65,000 impairment charge on trademarks both of which were recorded in operating expense.  There was no impairment of goodwill as it was determined that the estimated fair value of the reporting unit exceeded its carrying amount as of June 30, 2013.   See Footnote 11 for a description of our intangible assets.

We tested our intangible assets and goodwill for impairment as of April 30, 2014, our annual testing date.  We tested our intangible assets and goodwill for impairment due to our continued significant operating losses, negative cash flows, the estimated fair value of obligations due to Medtronic and due to the fact that we had a shareholders’ deficit as of the testing date. As part of this testing we fair valued all of our assets and liabilities as of this date using discounted cash flow analysis and forecasted future operating results.  Based on this testing, we determined that the fair value of the Company could no longer support the carrying value of the goodwill acquired as part of the Prostiva acquisition.  As a result, we recorded a non-cash impairment charge of $3,036,000 to fully impair our goodwill.   See footnote 10 for a description of our goodwill and related impairment charge.  There was no additional impairment of our long-lived assets as their estimated fair value exceeded their carrying values at the testing date.

Property and Equipment

Property and equipment are stated at cost.  Company owned Cooled ThermoTherapy control units and Prostiva RF Therapy generators located at customer sites for evaluation and long-term use programs are transferred from inventory and classified as property and equipment that are valued at cost to manufacture and depreciated on a straight-line basis over a useful life of four years.  Improvements that extend the useful lives of property and equipment are capitalized at cost and depreciated over their remaining useful lives.  Repairs and maintenance are charged to expense as incurred.  Depreciation is calculated using the straight-line method based upon estimated useful lives of three to seven years for machinery, equipment, furniture and vehicles.  Leasehold improvements are amortized over the shorter of the useful life of the assets or term of the lease.

Property and equipment, net consisted of the following (in thousands):

30-Jun-14

30-Jun-13

Leasehold improvements, equipment, furniture and vehicles

$

147

$

241

Computer equipment

13

32

Control units, generators and scopes

311

462

Total property and equipment, net

$

471

$

735

Depreciation expense for the years ended June 30, 2014 and 2013 was $360,000, and $401,000, respectively.

Contingent Consideration

Contingent consideration was recorded on the balance sheet at the acquisition date fair value based on the consideration expected to be transferred, discounted back to present value.  The discount rate used is determined at the time of measurement in accordance with accepted valuation methods.  The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense in operating loss.  Any changes in fair value will impact earnings in such reporting period until the contingencies are resolved.

Leases and Deferred Rent

We lease all of our office space. We evaluate and classify all of our leases as operating or capital leases for financial reporting purposes. As of June 30, 2014, all of our leases were accounted for as operating leases. For leases that contain rent escalations, we record the total rent payable during the lease term, as determined above, on a straight-line basis over the term of the lease and record the difference between the rents paid and the straight-line rent as a deferred rent.  Any lease incentives we receive for items such as leasehold improvements, we record a deferred credit for the amount of the lease incentive and amortize it over the lease term, which may or may not equal the amortization period of the leasehold improvements.

Warranty Costs

Certain of our products, including the Prostiva products, are covered by warranties against defects in material and workmanship for periods of up to 24 months.  We record a liability for warranty claims at the time of sale.  The amount of the liability is based on the trend in the historical ratio of product failure rates, material usage and service delivery costs to sales, the historical length of time between the sale and resulting warranty claim and other factors.

Warranty provisions and claims for the years ended June 30, 2014 and 2013 were as follows (in thousands):

Beginning

Warranty

Warranty

Ending

Years Ended

Balance

Provisions

Claims

Balance

30-Jun-14

$

58

$

36

$

-38

$

56

30-Jun-13

47

63

-52

58

Income Taxes

We utilize the asset and liability method of accounting for income taxes.  We recognize deferred tax liabilities or assets for the expected future tax consequences of temporary differences between the book and tax basis of assets and liabilities.  We regularly assess the likelihood that our deferred tax assets will be recovered from future taxable income.  We consider projected future taxable income and ongoing tax planning strategies in assessing the amount of the valuation allowance necessary to offset our deferred tax assets that will not be recoverable.  We have recorded and continue to carry a full valuation allowance against our gross deferred tax assets that will not reverse against deferred tax liabilities within the scheduled reversal period.  If we determine in the future that it is more likely than not that we will realize all or a portion of our deferred tax assets, we will adjust our valuation allowance in the period we make the determination.  We expect to provide a full valuation allowance on our future tax benefits until we can sustain a level of profitability that demonstrates our ability to realize these assets.  As of June 30, 2014, we carried a valuation allowance of $31.5 million against our net deferred tax assets.

Stock-Based Compensation

Stock-based compensation expense is based on the fair value of the award at the date of grant and is recognized over the requisite service period which corresponds to the vesting period.  Options typically vest 25 percent after the first year of service with the remaining vesting 1/36th each month thereafter.  Generally, options granted to non-employee directors are immediately exercisable at the date of grant while restricted stock awards generally vest after one year.  Options are priced based on the closing price of a share of our common stock at the date of grant.  The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model.  To determine the inputs for the Black-Scholes option pricing model, we use historical data to estimate expected volatility and the period of time that option grants are expected to be outstanding.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the estimated life of the option.  The range of these assumptions and the range of option pricing and number of options granted at the different grant dates will impact our calculation of the fair value of the awards and will therefore impact the amount of expense reflected in our statement of operations for any given period.  The Company also grants restricted stock awards which typically vest over a period of one to four years.  Fair value for restricted stock is based on the market price on the day of grant.  See Note 5 for additional discussion.

Net Loss Per Common Share

Basic loss per share was computed by dividing the net loss by the weighted average number of shares of common stock and participating securities outstanding during the periods presented.   Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding plus all potentially dilutive common shares that result from stock options, unless there is a net loss position, in which case diluted loss per share is the same as basic loss per share.  The number of shares used in earnings per share computations is as follows (in thousands):

For the years ended June 30,

2014

2013

Weighted average common shares outstanding - basic

21,219

20,703

Dilutive effect of stock options

-

-

Weighted average common shares outstanding - diluted

21,219

20,703

The dilutive effect of stock options in the above table excludes 1.7 million and 1.7 million of underlying options for which the exercise price was higher than the average market price for the years ended June 30, 2014 and 2013, respectively. In addition, there were no potentially dilutive stock options where the exercise price was lower than the average market price for the fiscal year ended June 30, 2014.  For the fiscal year ended June 30, 2013, there were dilutive potential common shares of 1,061 shares, where the exercise price was lower than the average market price and were excluded from diluted weighted average common shares outstanding as they would be anti-dilutive due to our net loss.

Research and Development Costs

Research and development costs are charged to expense as incurred.

Shipping and Handling Costs

The Company includes shipping and handling revenues in sales and shipping and handling costs in cost of goods sold.

Concentration of Cash

The Company deposits its cash in what management believes are high credit quality financial institutions. The balance, at times, may exceed federally insured limits.

Financial Instruments

The carrying amounts of our accounts receivable and accounts payable approximate fair value due to their short-term nature.    The fair value of the Company’s short and long-term debt, including deferred acquisition payments, is estimated based on our future projected cash flow streams which would be used to pay down the debt. As of June 30, 2014, the fair value of the Company’s short and long-term debt for purposes of the Company’s goodwill impairment analysis, including the deferred acquisition payments, was estimated at $1.9 million versus a carrying value of $10.4 million based on a market participant basis as required under the goodwill step 2 impairment test guidance.  The fair value of contingent consideration as disclosed in footnote 4 and the carrying amount of debt as disclosed in footnotes 12 and 13 are based on using the contractual obligations due under the terms of the agreement.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. These estimates and assumptions are based on management’s best estimates and judgments. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors that management believes to be reasonable under the circumstances, including the current economic environment. The Company adjusts such estimates and assumptions when facts and circumstances dictate. These include, among others, the change in the Prostiva capital equipment inventory as noted earlier, the continued difficult economic conditions, tight credit markets, Medicare reimbursement rate uncertainty, and a decline in consumer spending and confidence, all of which have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual amounts could differ significantly from those estimated at the time the financial statements are prepared. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the financial statements in future periods.

Reclassification

The balance sheet includes the reclassification of prior year inventory from current inventories to long-term inventories to conform with current year presentation.  The reclassification is related to additional inventories received subsequent to the Prostiva acquisition that should have been classified as long-term, as we do not expect to sell them within the next 12 months, which had been classified in current inventories.

Recently Issued Accounting Standard

In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract.  The requirements are effective for annual reporting periods beginning after December 15, 2016.  Early adoption is not permitted.  We are evaluating the impact of the amended revenue recognition guidance on our financial statements.

Liquidity

Liquidity	12 Months Ended
	Jun. 30, 2014
Liquidity [Abstract]	'
Liquidity	'
	3.Liquidity
	As of June 30, 2014, the Company had cash of $718,000.  The Company incurred net losses of $7,608,000 in fiscal year 2014 and $4,292,000 in the fiscal year ended 2013.  In addition, the Company has accumulated aggregate net losses from the inception of business through June 30, 2014 of $126.6 million.
	During the first quarter of fiscal 2012, the Company entered into a license agreement with Medtronic for the Prostiva RF Therapy System. The Company paid Medtronic $500,000 on September 6, 2011 for half of the $1,000,000 initial license fee, with the remaining $500,000 payable on the one-year anniversary of this date, September 6, 2012.  On June 28, 2013, we entered into a Restructuring Agreement with Medtronic related to the $7.5 million we owed to Medtronic under the Transaction Documents.  As part of this agreement we paid Medtronic $2.0 million in satisfaction of royalties earned for the 12 months ended September 6, 2012, the second half of the initial licensing fee, the license maintenance fee for the 12 month period ended September 6, 2012, for outstanding transition services fees, and for Prostiva inventory included as part of the acquisition and purchased subsequent to the acquisition.  In addition, we entered into a promissory note (the “Note”) with Medtronic for $5.3 million for the remaining amounts owed on Prostiva inventory acquired as part of the acquisition and purchased subsequent to the acquisition.  Interest on the Note accrues at a rate of 6 percent, compounded annually and is payable in five equal installments of principal plus accrued interest on March 31st of each year beginning on March 31, 2015. The $206,000 difference between the $7.5 million in obligations owed to Medtronic and the $2.0 million paid and the $5.3 million Note was recorded as a gain on debt extinguishment in fiscal year 2013.   The Company does not have adequate cash to repay the full outstanding principal amount of $5.3 million on the Note.  Any event of default under the Note may result in a loss of control of our business or bankruptcy.
	Under the license agreement, royalty payments for Prostiva products are paid one year in arrears based on the contract year.  The royalty payment due during the second quarter of fiscal year 2014 of $650,000 has not been paid as of June 30, 2014 or as of the date of filing this Annual Report on Form 10-K.  The $650,000 is included in the short-term deferred acquisition payment liability as of June 30, 2014.  In addition, we have not paid, as of June 30, 2014 or as of the date of filing this Annual Report on Form 10-K, the annual $65,000 licensing maintenance fee due on September 6, 2013 which is included in other accrued expenses as of June 30, 2014.  The non-payment does not entitle Medtronic to terminate the license agreement unless Medtronic provides written notice and an opportunity to cure the default.  The non-payment under the license agreement is also not an event of default under the Note unless Medtronic provides written notice and an opportunity to cure.  In the event of a material breach of the licensing agreement or other transaction documents, and Medtronic provides written notice to the Company and the Company fails to cure the breach, Medtronic may terminate the license agreement.  If the license agreement is terminated, the Company’s rights to sell the Prostiva product would be terminated.
	During the first quarter of fiscal 2013, the Company completed a follow-on offering in which we sold 5,980,000 shares of common stock at a price of $0.75 per share which contributed approximately $3.8 million of net proceeds after deducting underwriting discounts and commissions and other expenses payable by the Company.    However, as a result of the Company’s history of operating losses and negative cash flows from operations, and the need for additional working capital to support future operations, there is substantial doubt about our ability to continue as a going concern.  In addition, our line of credit with Silicon Valley Bank expired on June 30, 2014, and was not renewed.
	The Company’s cash may not be sufficient to sustain day-to-day operations for the next 12 months. The Company’s ability to continue as a going concern is dependent upon our ability to generate positive cash flows from our business and aggressively manage our expenses, including those associated with our acquisition of the Prostiva product line from Medtronic. The Company’s ability to continue as a going concern is also dependent upon avoiding an event of default under the Note and avoiding termination of the license relating to the Prostiva product, whether by negotiation with Medtronic, cure of any non-payment giving rise to an event of default or termination, or otherwise.
	The Company is considering all available alternatives to improve its cash and liquidity position.  In particular, the Company implemented a new sales strategy using a leaner and more efficient sales team which will continue to support our current customer base while also targeting new accounts which align with our value proposition of strong clinical outcomes and low costs in an attempt to generate revenues both from sales of our Cooled ThermoTherapy and Prostiva products in an amount sufficient to improve cash flow from our business.  The Company also implemented restructuring plans in January 2014 and again in April 2014 to reduce our cash utilization. The targeted annual savings from these restructurings total over $4 million, compared with the first half of fiscal year 2014.  In the fourth quarter, we received partial benefit of these changes (see Footnote 6 for further details).  The Company may also seek to improve its liquidity position by raising capital through additional indebtedness or an offering of its equity securities or both.  However, it may be difficult to raise additional capital through a debt offering due to the debt outstanding with Medtronic and their position as a secured lender.
	There is no assurance that our cash, cash generated from operations, if any, will be sufficient to fund our anticipated capital needs, operating expenses, (including payments under the licensing agreement), and Note repayments, particularly if product sales do not generate revenues in the amounts currently anticipated, if our operating costs are greater than anticipated or greater than our business can support.
	If the Company is unable to generate sufficient liquidity to meet its needs and in a timely manner, the Company may be required to further reduce expenses and curtail capital expenditures, sell assets, or suspend or discontinue operations.   In addition, there can be no assurance that the Company will be able to cure any potential event of default of the Note or cure any breach of any agreement with Medtronic, maintain compliance with its agreements with Medtronic,  raise additional capital, or improve its operating or financial performance.
	The financial statements as of and for the year ended June 30, 2014 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Jun. 30, 2014
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	4.Fair Value Measurements
	The Company follows the authoritative guidance on fair value measurements and disclosures with respect to assets and liabilities that are measured at fair value on both a recurring and non-recurring basis. Under this guidance, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The hierarchy is broken down into three levels defined as follows:
		•	Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities.
		•	Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly.
		•	Level 3 - Inputs are unobservable for the asset or liability.
	As part of the consideration for the Prostiva acquisition, the estimated royalty payments between the minimum and maximum amounts are considered contingent consideration.  The contingent consideration, including the payment up to the minimum obligation to transfer the license, is measured at fair value at the acquisition date and is remeasured to fair value at each reporting date until the contingency is resolved using Level 3 inputs.  The Level 3 inputs consist of the projected fiscal year of payments based on projected revenues and an estimated discount rate.  The fair value is determined by applying an appropriate discount rate that reflects the risk factors associated with the payment streams.  The changes in fair value that do not relate to the initial recognition of the liability as of the acquisition date are recognized in earnings.  The Company estimates the fair value of the future contingent consideration at $953,000 at June 30, 2014.  The Company recognized a reduction in fair value of contingent consideration of $105,000 during the fiscal year ended June 30, 2014 as a result of the reduction in the projected royalty payments in excess of contractual minimums.  There was no change in the fair value of non-contingent consideration.  The following table provides a reconciliation of the beginning and ending balances of the contingent consideration liability:
		Fiscal Year		Fiscal Year
	(in thousands)	2013		2014
	Beginning Balance - Contingent Consideration Liability	$	2,862	$	962
	Accretion expense		-11		96
	Change in fair value of contingent consideration		-1,380		-105
	Payments		-509		-
	Ending Balance - Contingent Consideration Liability	$	962	$	953
	As part of our annual testing, we tested our goodwill for impairment as of April 30, 2014.  As part of this impairment testing, we fair valued all of our assets and liabilities, many of which were based on discounted cash flows analysis and forecasted future operating results which represent Level 3 inputs.   As a result of our testing, we recorded a non-cash impairment charge of $3,036,000 to fully impair our goodwill.  The following table provides a reconciliation of the beginning and ending balances of our goodwill intangible asset:
		Fiscal Year
	(in thousands)	2014
	Beginning Balance - Goodwill	$	3,036
	Impairment charge		-3,036
	Ending Balance - Goodwill	$	-
	As a result of the delisting of our common stock from the NASDAQ exchange at the start of trading on June 7, 2013 and the continued decline of our stock price, we tested our long-lived assets and goodwill for impairment as of June 30, 2013.  Based on this impairment testing it was determined that our intangible assets acquired as part of the Prostiva acquisition with carrying amount of $1.9 million were impaired (See Note 11).  As a result, we wrote the intangible assets down to their implied fair value of $1.5 million and recorded an impairment charge of $434,000.   The fair value of patents and technology, customer base and trademark intangible assets was determined based on a discounted cash flow analysis of forecasted future operating results, which represents Level 3 assets measured at fair value on a nonrecurring basis subsequent to its original recognition.  The following table provides a reconciliation of the beginning and ending balances of intangible assets:
		Fiscal Year		Fiscal Year
	(in thousands)	2013		2014
	Beginning Balance - Intangible Assets	$	2,177	$	1,495
	Amortization expense		-248		-194
	Impairment charge		-434		-
	Ending Balance - Intangible Assets	$	1,495	$	1,301

Stock_Options_And_Restricted_S

Stock Options And Restricted Stock Awards	12 Months Ended
	Jun. 30, 2014
Stock Options And Restricted Stock Awards [Abstract]	'
Stock Options And Restricted Stock Awards	'
	5.  Stock Options and Restricted Stock Awards
	On November 16, 2012, our shareholders approved a new equity compensation plan, the Urologix, Inc. 2012 Stock Incentive Plan (the “2012 Plan”).  The 2012 Plan replaced our Amended and Restated 1991 Stock Option Plan (the “1991 Plan”) and provides stock incentive awards in the form of options (incentive and non-qualified), stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other awards in stock and/or cash.   As of June 30, 2014, we had reserved 1,860,328 shares of common stock under the 2012 Plan, which includes 260,328 expired and forfeited shares from the 1991 Plan and 1,319,354 shares were available for future grants. The number of shares available under the 2012 Plan will be increased by an amount equal to the number of shares subject to awards or options granted under the 1991 Plan, which would have become available for additional awards under the 1991 Plan by reason of the forfeiture, cancellation, expiration or termination of those awards.  Options expire 10 years from the date of grant and typically vest 25 percent after the first year of service with the remaining vesting 1/36th each month thereafter. The Company issues new shares when stock options are exercised.
	Amounts recognized in the financial statements related to stock-based compensation for the fiscal years ended June 30, 2014 and 2013 were as follows (in thousands):
			2014			2013
	Cost of goods sold		$	12		$	19
	Sales and marketing			53			46
	General and administrative			132			164
	Research and development			14			28
	Total cost of stock-based compensation		$	211		$	257
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model.  We use historical data to estimate expected volatility, the period of time that option grants are expected to be outstanding, as well as employee termination behavior.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the estimated life of the option.  For restricted stock awards, the fair value is calculated as the market price on date of grant and we amortize the fair value on a straight-line basis over the requisite service period of the award. The following weighted-average assumptions were used to estimate the fair value of options granted during the fiscal years ended June 30, 2014 and 2013 using the Black-Scholes option-pricing model:
		2014		2013
	Volatility	84.00%		72.00%
	Risk-free interest rate	0.70%		0.40%
	Expected option life	3.1 years		3.4 years
	Stock dividend yield	-		-
	A summary of our options and option activity for the fiscal year ended June 30, 2014 is as follows:
	Options Outstanding													Options Exercisable
										Weighted
										Avg.
										Remaining		Weighted				Weighted
								Outstanding as of		Contractual		Avg. Exercise		Exercisable as of		Avg. Exercise
	Range of Equity Prices							30-Jun-14		Life		Price		30-Jun-14		Price
	$	0.00			$	2.43			1,631,542		4.9	$	1.21		1,331,973	$	1.34
	$	2.44			$	4.86			57,500		2.1	$	3.20		57,500	$	3.20
	$	4.87			$	7.29			7,500		1.0	$	5.47		7,500	$	5.47
	$	7.30			$	14.58			7,500		0.1	$	12.23		7,500	$	12.23
									1,704,042		4.8	$	1.35		1,404,473	$	1.50
		Number of Options		Weighted-avg. Exercise Price Per Option	Weighted-avg. Remaining Contractual Term		Aggregate Intrinsic Value
	Outstanding at July 1, 2013	1,711,430	$	1.43		$	-
	Options granted	191,500		0.38
	Options forfeited	-88,063		0.66
	Options expired	-110,825		1.49
	Outstanding at June 30, 2014	1,704,042	$	1.35	4.79	$	-
	Exercisable at June 30, 2014	1,404,473	$	1.50	4.02	$	-
	There is no aggregate intrinsic value in the table above as our closing stock price of $0.18 and $0.17 on June 30, 2014 and June 28, 2013, respectively, the last trading day prior to June 30, 2013, was lower than all options outstanding and exercisable as of that date.
	The weighted average fair value of our options at their grant date was approximately $0.21 and $0.40 for options granted during the fiscal years ended June 30, 2014 and 2013, respectively.  No options were exercised in fiscal year 2014.  There was a negative intrinsic value of approximately $600 on options exercised during fiscal year 2013, as some options were exercised at a market price lower than the exercise price.
	A summary of the status of our non-vested options as of June 30, 2014 is as follows:
		Number of Options		Weighted-avg. Grant-Date Fair Value
	Non-vested at June 30, 2013	383,115	$	0.46
	Options granted	191,500		0.21
	Options forfeited	-88,063		0.34
	Options vested	-186,983		0.48
	Non-vested at June 30, 2014	299,569	$	0.32
	A summary of restricted stock award activity is as follows:
		Number of Restricted Stock Awards		Weighted-avg. Grant-Date Fair Value
	Non-vested at June 30, 2013	113,667	$	0.68
	Awards granted	377,500		0.28
	Awards forfeited	-35,000		0.38
	Awards vested	-109,865		0.67
	Non-vested at June 30, 2014	346,302	$	0.28
	As of June 30, 2014, total unrecognized compensation cost related to non-vested stock options and restricted stock awards granted under our plan was $86,000 and $24,000, respectively.  That cost is expected to be recognized over a weighted-average period of 2.0 years for non-vested stock options and 0.36 years for restricted stock awards.  The total fair value of options vested during the fiscal years ended June 30, 2014 and 2013 was $89,000 and  $140,000, respectively.

Restructuring

Restructuring	12 Months Ended
	Jun. 30, 2014
Restructuring [Abstract]	'
Restructuring	'
	6.Restructuring
	On January 3, 2014, the Company implemented a restructuring plan, reorganizing the Company’s operations and sales departments.  The restructuring expenses totaled approximately $41,000.  On April 10, 2014, the Company implemented a second restructuring plan, making additional changes to the Company’s operations and sales departments.  The restructuring included another reduction in work force and severance payments of approximately $45,000.  Of the $86,000 of expenses related to the two restructurings, approximately $26,000 was included in cost of goods sold and $60,000 was included in operating expense in fiscal year 2014.  A summary of the restructuring activity is as follows:
		Employee Termination Costs
	Balance as of June 30, 2013	$	-
	Restructuring charges		86
	Payments		-86
	Balance as of June 30, 2014	$	-
	The Company made the strategic decision to restructure the organization, including deploying a new distribution model and operational structure to refocus the allocation of company resources and improve the Company’s ability to achieve profitability and generate positive cash flow from operations. The strategic reorganization included implementing a leaner and more efficient sales team which will continue to support our customer base in a deployment designed to create a more profitable sales model.
	As a result of these restructurings cash utilization in the fourth quarter of fiscal year 2014 was $98,000, which included $80,000 of cash payments related to the April 10th restructuring for payments related to severance and accrued vacation.

Other_Accrued_Expenses

Other Accrued Expenses	12 Months Ended
	Jun. 30, 2014
Other Accrued Expenses [Abstract]	'
Other Accrued Expenses	'
	7.   Other Accrued Expenses
	Other accrued expenses is comprised of the following as of June 30 (in thousands):
		2014		2013
	Sales tax accrual	$	79	$	126
	Other		420		476
	Total other accrued expenses	$	499	$	602

Income_Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2014
Income Taxes [Abstract]	'
Income Taxes	'
	8 Income Taxes
	The components of income tax expense (benefit) for the periods ended June 30, 2014 and 2013 consist of the following (in thousands):
		For the fiscal year ended June 30,
		2014						2013
		Current		Deferred		Total		Current		Deferred		Total
	Federal	$	-	$	-33	$	-33	$	-	$	1	$	1
	State		20		-3		17		13		-		13
	Total	$	20	$	-36	$	-16	$	13	$	1	$	14
	A reconciliation of our statutory tax expense (benefit) to our actual tax expense (benefit) is as follows:
		For the years ended June 30,
		2014		2013
	Federal statutory rate at 34 percent	$	-2,592	$	-1,459
	State taxes, net of federal tax expense (benefit) and state valuation allowance		-231		-128
	Nondeductible expenses		34		17
	Stock-based compensation		29		55
	Adjustments to net operating losses and credits		918		5,562
	Adjustments to deferred tax assets		485		-
	Other		1		3
	Change in valuation allowance		1,340		-4,036
		$	-16	$	14
	The components of our net deferred tax assets and liabilities are as follows (in thousands):
		June 30,
		2014		2013
	Deferred Tax Assets:
	Non-Current:
	Net operating loss carry forward	$	27,861	$	27,131
	Definite-lived intangibles		2,851		2,414
	Alternative minimum tax credit		3		3
	Federal and state general business credits		886		865
	Non-qualified stock-based compensation		153		536
	Property, plant and equipment		80		64
	Current:
	Accrued expenses		582		318
	Gross deferred tax assets		32,416		31,331
	Deferred Tax Liabilities:
	Non-Current:
	Amortization of indefinite-lived intangible		-		-36
	Contingent consideration on acquisition		-900		-1,155
	Gross deferred tax liabilities		-900		-1,191
	Net deferred tax assets before valuation allowance		31,516		30,140
	Less: valuation allowance		-31,516		-30,176
	Total net deferred tax liability	$	-	$	-36
	The valuation allowance for deferred tax assets as of June 30, 2014 and 2013 was $31,516,000 and $30,176,000, respectively.  The total valuation allowance increased by $1,340,000 for the year ended June 30, 2014.  The total valuation allowance decreased $4,087,000 for the year ended June 30, 2013.  A significant portion of the current year increase in valuation allowance is attributable to generating NOL carryforward tax benefits.  In assessing the need for a valuation allowance, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The ultimate realized of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.  Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.
	Deferred tax assets relating to the tax benefits of employee stock option grants have been reduced to reflect exercises through the year ended June 30, 2014.  Certain exercises resulted in tax deductions in excess of previously recorded tax benefits.  The Company’s Federal NOL carryforwards of $77,534,000 referenced below as of June 30, 2014 include $541,000 of income tax deductions in excess of previously recorded tax benefits.  Although these additional tax deductions are reflected in NOL carryforwards referenced below, the related tax benefit of $184,000 will not be recognized until the deductions reduce taxes payable.  Accordingly, since the tax benefit does not reduce the Company’s current taxes payable in 2014, these tax benefits are not reflected in the Company’s deferred tax assets presented above.  The tax benefit of these excess deductions will be reflected as a credit to additional paid-in capital when and if recognized.
	As of June 30, 2014, the expiration dates and amounts of our net operating loss carryforwards and credits for federal income tax purposes are as follows (in thousands):
		Net Operating
	Years expiring	Loss		Credits
	30-Jun-15	$	-	$	-
	June 30, 2016 – June 30, 2020		21,389		-
	June 30, 2021 – June 30, 2025		19,481		115
	June 30, 2026 – June 30, 2034		36,664		552
		$	77,534	$	667
	The Company completed a Section 382 analysis of the net operating loss carryforwards through February 1, 2006.  Through that analysis it was determined that none of the remaining pre-February 1, 2006 net operating loss carryforwards are subject to a Section 382 limitation.  Net operating losses generated since February 1, 2006 have not been analyzed for any Section 382 limitations and therefore may or may not be fully realizable in the future.
	As of June 30, 2014, the Company had approximately $14,000 of unrecognized tax benefits related to state tax liabilities which would favorably impact the effective income tax rate in any future period, if recognized. During the year ended June 30, 2014, there were no significant changes to the total gross unrecognized tax benefits.  It is expected that the amount of unrecognized tax benefits for positions which we have identified will not change significantly in the next twelve months.
	We recognize accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense.  We file income tax returns in the United States (U.S.) federal jurisdiction as well as various state jurisdictions. We are subject to U.S. federal income tax examinations by tax authorities for fiscal years after 1998 due to unexpired net operating loss carryforwards originating in and subsequent to that fiscal year.  Income tax examinations we may be subject to for the various state taxing authorities vary by jurisdiction.

Deferred_Income

Deferred Income	12 Months Ended
	Jun. 30, 2014
Deferred Income [Abstract]	'
Deferred Income	'
	9.Deferred Income
	Deferred income as of June 30, 2014 and 2013 consists of deferred warranty service income of $6,000 and $5,000, respectively.   Deferred warranty service income is for prepayments made to us for warranty service contracts and is recognized over the contract period ranging from 12 to 24 months.

Goodwill

Goodwill	12 Months Ended
	Jun. 30, 2014
Goodwill [Abstract]	'
Goodwill	'
	10.  Goodwill
	The Company had approximately $3,036,000 of goodwill as of June 30, 2013, related to the acquisition of the Prostiva RF Therapy System on September 6, 2011.  Goodwill is tested for impairment annually on April 30th or more frequently if changes in circumstance or the occurrence of events suggests an impairment may exist.  We tested our goodwill for impairment due to our continued significant operating losses, negative cash flows, the estimated fair value of obligations due to Medtronic and due to the fact that we had a shareholders’ deficit as of the testing date. As part of this testing we fair valued all of our assets and liabilities as of this date using discounted cash flow analysis and forecasted future operating results. Based on this testing it was determined that the fair value of the Company could no longer support the carrying value of the goodwill.  As a result, we recorded a non-cash impairment charge of $3,036,000 to write off the full balance of goodwill as of the testing date.

Intangible_Assets

Intangible Assets	12 Months Ended
	Jun. 30, 2014
Intangible Assets [Abstract]	'
Intangible Assets	'
	11.Intangible Assets
	Intangible assets as of June 30, 2014 and 2013 consisted of the following (in thousands):
			30-Jun-14								30-Jun-13
									Net								Net
			Carrying		Accumulated				Carrying		Carrying		Accumulated				Carrying
			Value		Amortization		Impairment		Value		Value		Amortization		Impairment		Value
	Prostiva Acquisition
	Patents and Technology	$	1,529	$	-443	$	-274	$	812	$	1,529	$	-311	$	-274	$	944
	Customer Base		531		-154		-95		282		531		-108		-95		328
	Trademarks		325		-53		-65		207		325		-37		-65		223
	EDAP Acquisition
	Customer Base		2,300		-2,294		-		6		2,300		-2,270		-		30
	Other		74		-11		-		63		64		-2		-		62
	Total intangible assets	$	4,759		-2,955	$	-434	$	1,370	$	4,749		-2,728	$	-434	$	1,587
	Amortization expense associated with intangible assets for the fiscal years ended June 30, 2014 and 2013 was $227,000 and $274,000, respectively and includes amortization expense recorded in cost of goods sold.  As a result of the delisting of our common stock from the NASDAQ exchange at the start of trading on June 7, 2013 and the continued decline of our stock price, we tested our long-lived assets and goodwill for impairment as of June 30, 2013.  Based on this impairment testing it was determined that our intangible assets acquired as part of the Prostiva acquisition were impaired.  As a result, we recorded an impairment charge of $274,000 on our developed technology asset which was recorded in cost of goods sold, a $95,000 impairment charge on our customer base asset and a $65,000 impairment charge on trademarks both of which were recorded in operating expense. The fair value of patents and technology, customer base and trademark intangible assets was determined based on a discounted cash flow analysis of forecasted future operating results.
	All intangible assets are amortized using the straight-line method over their estimated remaining useful lives.  Patents and technology, customer base and trademarks related to the Prostiva acquisition are being amortized over 9 years, 9 years, and 16 years, respectively.  The customer base related to the EDAP acquisition is being amortized over its remaining useful life of 0.25 years, and other intangible assets related to patent costs are amortized upon issuance over their estimated useful lives.
	Future amortization expense related to the net carrying amount of intangible assets is estimated to be as follows (in thousands):
	Fiscal Years
	2015	$	205
	2016		199
	2017		199
	2018		198
	2019		196

Financing_Arrangement

Financing Arrangement	12 Months Ended
	Jun. 30, 2014
Financing Arrangement [Abstract]	'
Financing Arrangement	'
	12.Financing Arrangement
	Promissory Note
	On June 28, 2013, the Company entered into a promissory note (the “Note”) with Medtronic for $5.3 million for the remaining amounts owed on Prostiva inventory acquired as part of the acquisition and purchased subsequent to the acquisition.  Interest on the principal amount of the Note will accrue at the annual rate of 6%, compounded annually. The Note requires that the Company make five equal annual payments of principal and accrued interest on March 31 of each year beginning March 31, 2015. All amounts under the Note are due and payable on March 31, 2019 or earlier upon a Change of Control (as defined in the Note).  The Company may prepay the Note without penalty at any time. The Note is junior to a new lender that provides certain refinancing, but is senior in all respects (including right of payment) to all other existing or future indebtedness. The Note also specifies certain customary events of default that will entitle Medtronic, after any required notice, to declare the outstanding obligations immediately due and payable. The Note contains customary representations, warranties and covenants by the Company.
	Pursuant to the terms of a Security Agreement dated as of June 28, 2013 by and between Urologix and Medtronic, the Company’s obligations under the Note are secured by a security interest in all of the Company’s assets, specifically excluding intellectual property (but including accounts receivable and proceeds of intellectual property).

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
	Jun. 30, 2014
Commitments And Contingencies [Abstract]	'
Commitments And Contingencies	'
	13.Commitments and Contingencies
	Leases
	The Company leases its facility and certain equipment under non-cancelable operating leases that expire at various dates through fiscal year 2018.  Rent expense related to operating leases was approximately $229,000 and  $227,000 for the years ended June 30, 2014 and 2013, respectively.  On September 9, 2010, the Company entered into a new lease agreement with our current landlord, covering the same square footage, for a period of seventy-two months, effective August 1, 2010.     Future minimum annual lease commitments under non-cancelable operating leases with initial terms of one year or more are as follows:
		2015		2016		2017		2018		2019
	Building and equipment leases	$	228	$	231	$	32	$	5	$	-
	Prostiva Payments
	Prostiva payments are commitments related to the acquisition of the Prostiva RF Therapy product line from Medtronic on September 6, 2011.  In addition, on June 28, 2013, we entered into a promissory note (the “Note”) with Medtronic for $5.3 million for the remaining amounts owed on Prostiva inventory acquired as part of the acquisition and purchased subsequent to the acquisition.
			Fiscal Years
		2015			2016			2017			2018		2019
	Prostiva Payments
	Annual license maintenance fee	$	65			65			65			65		65
	Royalty obligations		650			650			650			650		650
	Note payments, including interest		1,323			1,323			1,323			1,323		1,323
		$	2,038		$	2,038		$	2,038		$	2,038	$	2,038
	Contingencies
	We have been and are involved in various legal proceedings and other matters that arise in the normal course of our business, including product liability claims that are inherent in the testing, production, marketing and sale of medical devices.  The ultimate liabilities, if any, cannot be determined at this time. However, based upon currently available information, we believe that the ultimate resolution of these matters will not have a material effect on the financial position, liquidity or results of operations of the Company.
	Major Vendor
	During the fiscal year ended June 30, 2014, the Company had purchases from one vendor that accounted for approximately 70 percent of total inventory purchases.  This vendor is the supplier of our Prostiva handpieces which accounted for approximately one-third of our revenue in fiscal year 2014.

Benefit_Plan

Benefit Plan	12 Months Ended
	Jun. 30, 2014
Benefit Plan [Abstract]	'
Benefit Plan	'
	14.Benefit Plan
	The Company provides a 401(k) savings plan to which eligible employees may make pretax payroll contributions up to the allowed limit of the Internal Revenue Service.  Company matching contributions are discretionary, and none have been made to date.

Gain_On_Demutualization

Gain On Demutualization	12 Months Ended
	Jun. 30, 2014
Gain On Demutualization [Abstract]	'
Gain On Demutualization	'
	15.Gain on Demutualization
	Urologix’s primary product liability insurance carrier since July 1, 2006 has been Medmarc Mutual Insurance Company (“Medmarc”). On June 27, 2012, Medmarc announced that it would become part of ProAssurance Corporation (“PRA”).  In order for Medmarc to be acquired by PRA, it was required to convert from a mutual insurance company to a stock insurance company through a demutualization process.  Concurrently, upon demutualization, PRA would purchase the newly-issued shares of Medmarc common stock. Under the terms of the demutualization, Urologix’s calculated portion of the cash consideration to be received was approximately $321,000. The receipt of the consideration had no direct effect on the Company’s existing insurance policy or coverage.  On December 4, 2012, the majority of eligible members voted to approve the demutualization of Medmarc, and in accordance with the Plan of Conversion agreement, Urologix was eligible to receive the cash consideration upon the completion of the acquisition, or January 1, 2013.  Urologix received the cash consideration of $321,000 for the demutualization in January, 2013 and recognized a gain from the demutualization in fiscal year 2013.

Significant_Accounting_Policie1

Significant Accounting Policies (Policy)	12 Months Ended
	Jun. 30, 2014
Significant Accounting Policies [Abstract]	'
Revenue Recognition	'
	Revenue Recognition
	We recognize revenue from the sale of Cooled ThermoTherapy control units upon delivery to the customer, which include urologists, urology practices, mobile units, clinics and hospitals. We recognize revenue from the sale of Prostiva generators upon shipment to the customer. Revenue is recognized in accordance with generally accepted accounting principles as outlined in Accounting Standards Codification (“ASC”) 605-10-S99, Revenue Recognition, which requires that four basic criteria be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) product delivery has occurred or services have been rendered.  The Company recognizes revenue as products are shipped based on FOB shipping point terms when title passes to customers.  In addition to our sales of Cooled ThermoTherapy control units and Prostiva generators, we place our control units and generators with customers free of charge under a variety of programs for both evaluation and long-term use, and also provide access to Cooled ThermoTherapy and Prostiva RF Therapy treatments via our Urologix mobile service. We retain title to the control units and generators placed with our customers for evaluation and longer-term use. These programs, as well as our Urologix mobile service, are designed to expand access to our technology, and thus expand the market for our single-use treatment catheters and Prostiva handpieces. The free use of our Cooled ThermoTherapy control units and Prostiva generators are bundled with the sale of single-use treatment catheters or Prostiva handpieces and scopes, respectively, and are considered a single unit of accounting. Revenue from the bundled sales is recognized when the single-use treatment catheters or handpieces and scopes are shipped to our customers. Revenue from our mobile service is recognized upon treatment of the patient. Revenue for extended warranty service contracts is deferred and recognized over the contract period on a straight-line basis. We record a provision for estimated sales returns on product sales in the same period as the related revenue is recorded. The provision for estimated sales returns is based on historical sales returns, analysis of credit memo data and specific customer-based circumstances. Should actual sales returns differ from our estimates, revisions to the sales return reserve would be required. Sales and use taxes are reported on a net basis, excluding them from revenue.
Allowance For Doubtful Accounts	'
	Allowance for Doubtful Accounts
	We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  We consider factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay when determining the adequacy of the allowance.  Invoices are generally due 30 days after presentation.  Accounts receivable over 30 days are considered past due.  Accounts receivable are written-off after management determines they are uncollectible.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or market on a first-in, first-out (FIFO) basis
Valuation Of Long-Lived Assets And Goodwill	'
	Valuation of Long-Lived Assets and Goodwill
	We assess the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An asset or asset group is considered impaired if its carrying amount exceeds the undiscounted future net cash flows the asset or asset group is expected to generate. If an asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. If estimated fair value is less than the book value, the asset is written down to the estimated fair value and an impairment loss is recognized.
	Goodwill is tested for impairment annually on April 30th or more frequently if changes in circumstance or the occurrence of events suggests an impairment may exist. To determine if there is goodwill impairment, the fair value of the reporting unit is compared to its carrying amount.  If the fair value of a reporting unit is less than its carrying value, or if there is a shareholders’ deficit, an impairment loss is recorded to the extent that the fair value of the goodwill is less than the carrying value of the goodwill. The test for impairment requires us to make several estimates about fair value, most of which are based on projected future cash flows.
	Considerable management judgment is necessary in estimating future cash flows and other factors affecting the valuation of long-lived assets and goodwill, including the operating and macroeconomic factors that may affect them. We use historical financial information, internal plans and projections and industry information in making such estimates.
	As a result of the delisting of our common stock from the NASDAQ exchange on June 7, 2013 and the continued decline of our stock price, we tested our long-lived assets and goodwill for impairment as of June 30, 2013.  Based on this impairment testing it was determined that our intangible assets acquired as part of the Prostiva acquisition were impaired.  As a result, we recorded an impairment charge of $274,000 on our developed technology asset which was recorded in cost of goods sold, a $95,000 impairment charge on our customer base asset and a $65,000 impairment charge on trademarks both of which were recorded in operating expense.  There was no impairment of goodwill as it was determined that the estimated fair value of the reporting unit exceeded its carrying amount as of June 30, 2013.   See Footnote 11 for a description of our intangible assets.
	We tested our intangible assets and goodwill for impairment as of April 30, 2014, our annual testing date.  We tested our intangible assets and goodwill for impairment due to our continued significant operating losses, negative cash flows, the estimated fair value of obligations due to Medtronic and due to the fact that we had a shareholders’ deficit as of the testing date. As part of this testing we fair valued all of our assets and liabilities as of this date using discounted cash flow analysis and forecasted future operating results.  Based on this testing, we determined that the fair value of the Company could no longer support the carrying value of the goodwill acquired as part of the Prostiva acquisition.  As a result, we recorded a non-cash impairment charge of $3,036,000 to fully impair our goodwill.   See footnote 10 for a description of our goodwill and related impairment charge.  There was no additional impairment of our long-lived assets as their estimated fair value exceeded their carrying values at the testing date.
Property And Equipment	'
	Property and Equipment
	Property and equipment are stated at cost.  Company owned Cooled ThermoTherapy control units and Prostiva RF Therapy generators located at customer sites for evaluation and long-term use programs are transferred from inventory and classified as property and equipment that are valued at cost to manufacture and depreciated on a straight-line basis over a useful life of four years.  Improvements that extend the useful lives of property and equipment are capitalized at cost and depreciated over their remaining useful lives.  Repairs and maintenance are charged to expense as incurred.  Depreciation is calculated using the straight-line method based upon estimated useful lives of three to seven years for machinery, equipment, furniture and vehicles.  Leasehold improvements are amortized over the shorter of the useful life of the assets or term of the lease.
Contingent Consideration	'
	Contingent Consideration
	Contingent consideration was recorded on the balance sheet at the acquisition date fair value based on the consideration expected to be transferred, discounted back to present value.  The discount rate used is determined at the time of measurement in accordance with accepted valuation methods.  The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense in operating loss.  Any changes in fair value will impact earnings in such reporting period until the contingencies are resolved.
Leases And Deferred Rent	'
	Leases and Deferred Rent
	We lease all of our office space. We evaluate and classify all of our leases as operating or capital leases for financial reporting purposes. As of June 30, 2014, all of our leases were accounted for as operating leases. For leases that contain rent escalations, we record the total rent payable during the lease term, as determined above, on a straight-line basis over the term of the lease and record the difference between the rents paid and the straight-line rent as a deferred rent.  Any lease incentives we receive for items such as leasehold improvements, we record a deferred credit for the amount of the lease incentive and amortize it over the lease term, which may or may not equal the amortization period of the leasehold improvements.
Warranty Costs	'
	Warranty Costs
	Certain of our products, including the Prostiva products, are covered by warranties against defects in material and workmanship for periods of up to 24 months.  We record a liability for warranty claims at the time of sale.  The amount of the liability is based on the trend in the historical ratio of product failure rates, material usage and service delivery costs to sales, the historical length of time between the sale and resulting warranty claim and other factors.
Income Taxes	'
	Income Taxes
	We utilize the asset and liability method of accounting for income taxes.  We recognize deferred tax liabilities or assets for the expected future tax consequences of temporary differences between the book and tax basis of assets and liabilities.  We regularly assess the likelihood that our deferred tax assets will be recovered from future taxable income.  We consider projected future taxable income and ongoing tax planning strategies in assessing the amount of the valuation allowance necessary to offset our deferred tax assets that will not be recoverable.  We have recorded and continue to carry a full valuation allowance against our gross deferred tax assets that will not reverse against deferred tax liabilities within the scheduled reversal period.  If we determine in the future that it is more likely than not that we will realize all or a portion of our deferred tax assets, we will adjust our valuation allowance in the period we make the determination.  We expect to provide a full valuation allowance on our future tax benefits until we can sustain a level of profitability that demonstrates our ability to realize these assets.  As of June 30, 2014, we carried a valuation allowance of $31.5 million against our net deferred tax assets.
Stock-Based Compensation	'
	Stock-Based Compensation
	Stock-based compensation expense is based on the fair value of the award at the date of grant and is recognized over the requisite service period which corresponds to the vesting period.  Options typically vest 25 percent after the first year of service with the remaining vesting 1/36th each month thereafter.  Generally, options granted to non-employee directors are immediately exercisable at the date of grant while restricted stock awards generally vest after one year.  Options are priced based on the closing price of a share of our common stock at the date of grant.  The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model.  To determine the inputs for the Black-Scholes option pricing model, we use historical data to estimate expected volatility and the period of time that option grants are expected to be outstanding.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the estimated life of the option.  The range of these assumptions and the range of option pricing and number of options granted at the different grant dates will impact our calculation of the fair value of the awards and will therefore impact the amount of expense reflected in our statement of operations for any given period.  The Company also grants restricted stock awards which typically vest over a period of one to four years.  Fair value for restricted stock is based on the market price on the day of grant.  See Note 5 for additional discussion.
Net Loss Per Common Share	'
	Net Loss Per Common Share
	Basic loss per share was computed by dividing the net loss by the weighted average number of shares of common stock and participating securities outstanding during the periods presented.   Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding plus all potentially dilutive common shares that result from stock options, unless there is a net loss position, in which case diluted loss per share is the same as basic loss per share.
Research And Development Costs	'
	Research and Development Costs
	Research and development costs are charged to expense as incurred.
Shipping And Handling Costs	'
	Shipping and Handling Costs
	The Company includes shipping and handling revenues in sales and shipping and handling costs in cost of goods sold.
Concentration Of Cash	'
	Concentration of Cash
	The Company deposits its cash in what management believes are high credit quality financial institutions. The balance, at times, may exceed federally insured limits.
Financial Instruments	'
	Financial Instruments
	The carrying amounts of our accounts receivable and accounts payable approximate fair value due to their short-term nature.    The fair value of the Company’s short and long-term debt, including deferred acquisition payments, is estimated based on our future projected cash flow streams which would be used to pay down the debt. As of June 30, 2014, the fair value of the Company’s short and long-term debt for purposes of the Company’s goodwill impairment analysis, including the deferred acquisition payments, was estimated at $1.9 million versus a carrying value of $10.4 million based on a market participant basis as required under the goodwill step 2 impairment test guidance.  The fair value of contingent consideration as disclosed in footnote 4 and the carrying amount of debt as disclosed in footnotes 12 and 13 are based on using the contractual obligations due under the terms of the agreement.
Use Of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. These estimates and assumptions are based on management’s best estimates and judgments. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors that management believes to be reasonable under the circumstances, including the current economic environment. The Company adjusts such estimates and assumptions when facts and circumstances dictate. These include, among others, the change in the Prostiva capital equipment inventory as noted earlier, the continued difficult economic conditions, tight credit markets, Medicare reimbursement rate uncertainty, and a decline in consumer spending and confidence, all of which have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual amounts could differ significantly from those estimated at the time the financial statements are prepared. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the financial statements in future periods.
Reclassification	'
	Reclassification
	The balance sheet includes the reclassification of prior year inventory from current inventories to long-term inventories to conform with current year presentation.  The reclassification is related to additional inventories received subsequent to the Prostiva acquisition that should have been classified as long-term, as we do not expect to sell them within the next 12 months, which had been classified in current inventories.
Recently Issued Accounting Standards	'
	Recently Issued Accounting Standard
	In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract.  The requirements are effective for annual reporting periods beginning after December 15, 2016.  Early adoption is not permitted.  We are evaluating the impact of the amended revenue recognition guidance on our financial statements.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2014
Significant Accounting Policies [Abstract]	'
Schedule Of Allowance For Doubtful Accounts	'
				Beginning									Ending
	Years Ended			Balance			Provisions			Write-offs			Balance
	30-Jun-14		$	79		$	10		$	-13		$	76
	30-Jun-13			83			38			-42			79
Schedule Of Inventories	'
	(in thousands)	30-Jun-14			30-Jun-13
	Raw materials	$	685		$	734
	Work-in-process		127			112
	Finished goods		726			1,768
	Total inventories	$	1,538		$	2,614
Schedule Of Property, Plant And Equipment	'
		30-Jun-14			30-Jun-13
	Leasehold improvements, equipment, furniture and vehicles	$	147		$	241
	Computer equipment		13			32
	Control units, generators and scopes		311			462
	Total property and equipment, net	$	471		$	735
Schedule Of Product Warranty Liability	'
			Beginning			Warranty			Warranty			Ending
	Years Ended		Balance			Provisions			Claims			Balance
	30-Jun-14	$	58		$	36		$	-38		$	56
	30-Jun-13		47			63			-52			58
Schedule Of Shares Used In Earnings Per Share Computation	'
			For the years ended June 30,
			2014			2013
	Weighted average common shares outstanding - basic			21,219			20,703
	Dilutive effect of stock options			-			-
	Weighted average common shares outstanding - diluted			21,219			20,703

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2014
Goodwill [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Reconciliation Of Contingent Consideration Liability, Goodwill And Intangible Assets	'
		Fiscal Year
	(in thousands)	2014
	Beginning Balance - Goodwill	$	3,036
	Impairment charge		-3,036
	Ending Balance - Goodwill	$	-
Finite-Lived Intangible Assets [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Reconciliation Of Contingent Consideration Liability, Goodwill And Intangible Assets	'
		Fiscal Year		Fiscal Year
	(in thousands)	2013		2014
	Beginning Balance - Intangible Assets	$	2,177	$	1,495
	Amortization expense		-248		-194
	Impairment charge		-434		-
	Ending Balance - Intangible Assets	$	1,495	$	1,301
Contingent Consideration Liability [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Reconciliation Of Contingent Consideration Liability, Goodwill And Intangible Assets	'
		Fiscal Year		Fiscal Year
	(in thousands)	2013		2014
	Beginning Balance - Contingent Consideration Liability	$	2,862	$	962
	Accretion expense		-11		96
	Change in fair value of contingent consideration		-1,380		-105
	Payments		-509		-
	Ending Balance - Contingent Consideration Liability	$	962	$	953

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2014
Stock Options And Restricted Stock Awards [Abstract]	'
Amounts Recognized In Financial Statements Related To Stock-Based Compensation	'
			2014			2013
	Cost of goods sold		$	12		$	19
	Sales and marketing			53			46
	General and administrative			132			164
	Research and development			14			28
	Total cost of stock-based compensation		$	211		$	257
Assumptions Used To Estimate Fair Value Of Options Granted	'
		2014		2013
	Volatility	84.00%		72.00%
	Risk-free interest rate	0.70%		0.40%
	Expected option life	3.1 years		3.4 years
	Stock dividend yield	-		-
Summary Of Stock Option Activity By Exercise Price	'
	Options Outstanding													Options Exercisable
										Weighted
										Avg.
										Remaining		Weighted				Weighted
								Outstanding as of		Contractual		Avg. Exercise		Exercisable as of		Avg. Exercise
	Range of Equity Prices							30-Jun-14		Life		Price		30-Jun-14		Price
	$	0.00			$	2.43			1,631,542		4.9	$	1.21		1,331,973	$	1.34
	$	2.44			$	4.86			57,500		2.1	$	3.20		57,500	$	3.20
	$	4.87			$	7.29			7,500		1.0	$	5.47		7,500	$	5.47
	$	7.30			$	14.58			7,500		0.1	$	12.23		7,500	$	12.23
									1,704,042		4.8	$	1.35		1,404,473	$	1.50
Summary Of Stock Option Activity	'
		Number of Options		Weighted-avg. Exercise Price Per Option	Weighted-avg. Remaining Contractual Term		Aggregate Intrinsic Value
	Outstanding at July 1, 2013	1,711,430	$	1.43		$	-
	Options granted	191,500		0.38
	Options forfeited	-88,063		0.66
	Options expired	-110,825		1.49
	Outstanding at June 30, 2014	1,704,042	$	1.35	4.79	$	-
	Exercisable at June 30, 2014	1,404,473	$	1.50	4.02	$	-
Summary Of Non-Vested Options	'
		Number of Options		Weighted-avg. Grant-Date Fair Value
	Non-vested at June 30, 2013	383,115	$	0.46
	Options granted	191,500		0.21
	Options forfeited	-88,063		0.34
	Options vested	-186,983		0.48
	Non-vested at June 30, 2014	299,569	$	0.32
Summary Of Non-Vested Restricted Stock Activitiy	'
		Number of Restricted Stock Awards		Weighted-avg. Grant-Date Fair Value
	Non-vested at June 30, 2013	113,667	$	0.68
	Awards granted	377,500		0.28
	Awards forfeited	-35,000		0.38
	Awards vested	-109,865		0.67
	Non-vested at June 30, 2014	346,302	$	0.28

Restructuring_Tables

Restructuring (Tables)	12 Months Ended
	Jun. 30, 2014
Restructuring [Abstract]	'
Schedule Of Restructuring Activity	'
		Employee Termination Costs
	Balance as of June 30, 2013	$	-
	Restructuring charges		86
	Payments		-86
	Balance as of June 30, 2014	$	-

Other_Accrued_Expenses_Tables

Other Accrued Expenses (Tables)	12 Months Ended
	Jun. 30, 2014
Other Accrued Expenses [Abstract]	'
Other Accrued Expenses	'
		2014		2013
	Sales tax accrual	$	79	$	126
	Other		420		476
	Total other accrued expenses	$	499	$	602

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2014
Income Taxes [Abstract]	'
Schedule Of Components Of Income Tax Expense (Benefit)	'
		For the fiscal year ended June 30,
		2014						2013
		Current		Deferred		Total		Current		Deferred		Total
	Federal	$	-	$	-33	$	-33	$	-	$	1	$	1
	State		20		-3		17		13		-		13
	Total	$	20	$	-36	$	-16	$	13	$	1	$	14
Reconciliation Of StatutoryTax Expense (Benefit) To Actual Tax Expense (Benefit)	'
		For the years ended June 30,
		2014		2013
	Federal statutory rate at 34 percent	$	-2,592	$	-1,459
	State taxes, net of federal tax expense (benefit) and state valuation allowance		-231		-128
	Nondeductible expenses		34		17
	Stock-based compensation		29		55
	Adjustments to net operating losses and credits		918		5,562
	Adjustments to deferred tax assets		485		-
	Other		1		3
	Change in valuation allowance		1,340		-4,036
		$	-16	$	14
Schedule Of Components Of Net Deferred Tax Assets And Liabilities	'
		June 30,
		2014		2013
	Deferred Tax Assets:
	Non-Current:
	Net operating loss carry forward	$	27,861	$	27,131
	Definite-lived intangibles		2,851		2,414
	Alternative minimum tax credit		3		3
	Federal and state general business credits		886		865
	Non-qualified stock-based compensation		153		536
	Property, plant and equipment		80		64
	Current:
	Accrued expenses		582		318
	Gross deferred tax assets		32,416		31,331
	Deferred Tax Liabilities:
	Non-Current:
	Amortization of indefinite-lived intangible		-		-36
	Contingent consideration on acquisition		-900		-1,155
	Gross deferred tax liabilities		-900		-1,191
	Net deferred tax assets before valuation allowance		31,516		30,140
	Less: valuation allowance		-31,516		-30,176
	Total net deferred tax liability	$	-	$	-36
Schedule Of Expiration Dates And Net Operating Loss Carryforwards And Credits	'
		Net Operating
	Years expiring	Loss		Credits
	30-Jun-15	$	-	$	-
	June 30, 2016 – June 30, 2020		21,389		-
	June 30, 2021 – June 30, 2025		19,481		115
	June 30, 2026 – June 30, 2034		36,664		552
		$	77,534	$	667

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2014
Intangible Assets [Abstract]	'
Schedule Of Intangible Assets	'
			30-Jun-14								30-Jun-13
									Net								Net
			Carrying		Accumulated				Carrying		Carrying		Accumulated				Carrying
			Value		Amortization		Impairment		Value		Value		Amortization		Impairment		Value
	Prostiva Acquisition
	Patents and Technology	$	1,529	$	-443	$	-274	$	812	$	1,529	$	-311	$	-274	$	944
	Customer Base		531		-154		-95		282		531		-108		-95		328
	Trademarks		325		-53		-65		207		325		-37		-65		223
	EDAP Acquisition
	Customer Base		2,300		-2,294		-		6		2,300		-2,270		-		30
	Other		74		-11		-		63		64		-2		-		62
	Total intangible assets	$	4,759		-2,955	$	-434	$	1,370	$	4,749		-2,728	$	-434	$	1,587
Future Amortization Expense Related To Net Carrying Amount Of Intangible Assets	'
	Fiscal Years
	2015	$	205
	2016		199
	2017		199
	2018		198
	2019		196

Commitments_And_Contingencies_

Commitments And Contingencies (Tables)	12 Months Ended
	Jun. 30, 2014
Commitments And Contingencies [Abstract]	'
Schedule Of Future Minimal Annual Lease Commitments	'
		2015		2016		2017		2018		2019
	Building and equipment leases	$	228	$	231	$	32	$	5	$	-
Schedule Of Estimated Prostiva Payments	'
			Fiscal Years
		2015			2016			2017			2018		2019
	Prostiva Payments
	Annual license maintenance fee	$	65			65			65			65		65
	Royalty obligations		650			650			650			650		650
	Note payments, including interest		1,323			1,323			1,323			1,323		1,323
		$	2,038		$	2,038		$	2,038		$	2,038	$	2,038

Significant_Accounting_Policie3

Significant Accounting Policies (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Jun. 30, 2014	Jun. 30, 2013
Accounting Policies [Line Items]	'	'	'
Inventory write-down	$739,000	'	'
Finished goods	'	726,000	1,768,000
Long-term inventories	'	141,000	1,043,000
Impairment of long-lived assets	'	'	160,000
Impairment of goodwill	'	3,036,000	0
Depreciation expense	'	360,000	401,000
Maximum number of months covered by warranties	'	'24 months	'
Valuation allowance amounts	'	31,516,000	30,176,000
Share-based compensation, percentage vest after first year	'	25.00%	'
Share-based compensation, percentage of options vesting each month after year one	'	2.78%	'
Estimated fair value of short and long-term debt	'	1,900,000	'
Carrying value of short and long-term debt and deferred acquisition payments	'	10,400,000	'
Developed Technology [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Impairment of long-lived assets	'	274,000	'
Customer Base [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Impairment of long-lived assets	'	95,000	'
Trademarks [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Impairment of long-lived assets	'	65,000	'
Cooled Thermo Therapy Control Units And Prostive RF Therapy Generators [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Machinery, equipment, furniture and vehicles, useful life, years	'	'4 years	'
Provista Acquisition [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Inventory write-down	$504,000	'	'
Exercise Price Above Average Market Price [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Potentially dilutive stock options excluded from diluted weighted average common shares outstanding	'	1,700,000	1,700,000
Exercise Price Below Average Market Price [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Potentially dilutive stock options excluded from diluted weighted average common shares outstanding	'	0	1,061
Minimum [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Machinery, equipment, furniture and vehicles, useful life, years	'	'3 years	'
Minimum [Member] | Restricted Stock [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Vesting period	'	'1 year	'
Maximum [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Machinery, equipment, furniture and vehicles, useful life, years	'	'7 years	'
Maximum [Member] | Restricted Stock [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Vesting period	'	'4 years	'

Significant_Accounting_Policie4

Significant Accounting Policies (Schedule Of Allowance For Doubtful Accounts) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Significant Accounting Policies [Abstract]	'	'
Beginning balance	$79	$83
Provisions	10	38
Write-offs	-13	-42
Ending balance	$76	$79

Significant_Accounting_Policie5

Significant Accounting Policies (Schedule Of Inventories) (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Significant Accounting Policies [Abstract]	'	'
Raw materials	$685	$734
Work-in-process	127	112
Finished goods	726	1,768
Total inventories	$1,538	$2,614

Significant_Accounting_Policie6

Significant Accounting Policies (Schedule Of Property, Plant And Equipment) (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Net	$471	$735
Leasehold Improvements, Equipment, Furniture and Vehicles [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Net	147	241
Computer Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Net	13	32
Control Units, Generators And Scopes [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Net	$311	$462

Significant_Accounting_Policie7

Significant Accounting Policies (Schedule Of Product Warranty Liability) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Significant Accounting Policies [Abstract]	'	'
Beginning Balance	$58	$47
Warranty Provisions	36	63
Warranty Claims	-38	-52
Ending Balance	$56	$58

Significant_Accounting_Policie8

Significant Accounting Policies (Schedule Of Shares Used In Earnings Per Share Computation) (Details)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Significant Accounting Policies [Abstract]	'	'
Weighted average common shares outstanding - basic	21,219	20,703
Dilutive effect of stock options	'	'
Weighted average common shares outstanding - dilutive	21,219	20,703

Liquidity_Details

Liquidity (Details) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended
	Jun. 28, 2013	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 28, 2013	Sep. 06, 2012	Jun. 30, 2012	Sep. 06, 2011
Cash and cash equivalents	'	'	$718,000	$2,290,000	'	'	$1,899,000	'
Net losses	'	'	-7,608,000	-4,292,000	'	'	'	'
Accumulated aggregate net losses from inception of business	'	'	-126,626,000	-119,018,000	'	'	'	'
Licensing fee paid	'	'	'	'	'	'	'	500,000
Total initial licensing fee	'	'	'	'	'	'	'	1,000,000
Amount owed for current outstanding Prostiva liabilities prior to Restructuring Agreement	'	'	'	'	'	500,000	'	'
Amount of liabilities restructured	'	'	'	'	7,500,000	'	'	'
Cash paid related to Restructuring Agreement.	2,000,000	'	'	'	'	'	'	'
Promissory note payable	'	'	'	'	5,300,000	'	'	'
Promissory note, interest rate	'	'	6.00%	'	'	'	'	'
Gain on debt extinguishment	'	'	'	206,000	'	'	'	'
Accrued royalties	'	'	650,000	'	'	'	'	'
License maintence fee	'	'	65,000	'	'	'	'	'
Shares of common stock sold	'	5,980,000	'	'	'	'	'	'
Shares price of common stock sold	'	$0.75	'	'	'	'	'	'
Net proceeds from secondary offering	'	'	'	3,814,000	'	'	'	'
Scenario, Forecast [Member]	'	'	'	'	'	'	'	'
Estimated expense reduction due to restructuring	'	'	$4,000,000	'	'	'	'	'

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Business Acquisition [Line Items]	'	'	'
Estimated fair value of future contingent consideration	$953,000	$962,000	$2,862,000
Reduction in fair value of contingent consideration	-105,000	-1,380,000	'
Carrying value of acquired intangible assets	1,900,000	'	'
Impairment of goodwill	3,036,000	0	'
Intangible assets, implied fair value	1,370,000	1,587,000	'
Impairment charge	'	160,000	'
Prostiva [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Intangible assets, implied fair value	1,301,000	1,495,000	2,177,000
Impairment charge	'	$434,000	'

Fair_Value_Measurements_Reconc

Fair Value Measurements (Reconciliation Of Contingent Consideration Liability) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Fair Value Measurements [Abstract]	'	'
Beginning balance	$962	$2,862
Accretion expense	96	-11
Change in fair value of contingent consideration	-105	-1,380
Payments	'	-509
Ending balance	$953	$962

Fair_Value_Measurements_Reconc1

Fair Value Measurements (Reconciliation Of Goodwill) (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Fair Value Measurements [Abstract]	'	'
Goodwill, Beginning Balance	$3,036,000	'
Impairment charge	-3,036,000	0
Goodwill, Ending Balance	'	$3,036,000

Fair_Value_Measurements_Reconc2

Fair Value Measurements (Reconciliation Of Long-Lived Assets) (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Business Acquisition [Line Items]	'	'
Beginning Balance - Intangible Assets	$1,587,000	'
Amortization expense	-95,000	-104,000
Impairment charge	'	-160,000
Ending Balance - Intangible Assets	1,370,000	1,587,000
Prostiva [Member]	'	'
Business Acquisition [Line Items]	'	'
Beginning Balance - Intangible Assets	1,495,000	2,177,000
Amortization expense	-194,000	-248,000
Impairment charge	'	-434,000
Ending Balance - Intangible Assets	$1,301,000	$1,495,000

Stock_Options_And_Restricted_S1

Stock Options And Restricted Stock Awards (Narrative) (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 28, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Shares of common stock reserved	1,860,328	'	'
Shares available for future grants	1,319,354	'	'
Options expiration period, years	'10 years	'	'
Vesting percentage after first year of service	25.00%	'	'
Share-based compensation, percentage of options vesting each month after year one	2.78%	'	'
Closing stock price	$0.18	'	$0.17
Weighted average grant date fair value	$0.21	$0.40	'
Number of options exercised	0	'	'
Intrinsic value of options exercised	'	($600)	'
Fair value of options vested	89,000	140,000	'
1991 Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Shares expired and forfeited	260,328	'	'
Non-Vested Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Total unrecognized compensation cost	86,000	'	'
Weighted-average period for recognition of compensation cost, in years	'2 years	'	'
Restricted Stock [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Total unrecognized compensation cost	$24,000	'	'
Weighted-average period for recognition of compensation cost, in years	'4 months 10 days	'	'

Stock_Options_And_Restricted_S2

Stock Options And Restricted Stock Awards (Amounts Recognized In Financial Statements Related To Stock-Based Compensation) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total cost of stock-based compensation	$211	$257
Cost Of Goods Sold [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total cost of stock-based compensation	12	19
Sales And Marketing [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total cost of stock-based compensation	53	46
General And Administrative [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total cost of stock-based compensation	132	164
Research And Development [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total cost of stock-based compensation	$14	$28

Stock_Options_And_Restricted_S3

Stock Options And Restricted Stock Awards (Assumptions Used To Estimate Fair Value Of Options Granted) (Details)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Stock Options And Restricted Stock Awards [Abstract]	'	'
Volatility	84.00%	72.00%
Risk-free interest rate	0.70%	0.40%
Expected option life	'3 years 1 month 6 days	'3 years 4 months 24 days

Stock_Options_And_Restricted_S4

Stock Options And Restricted Stock Awards (Summary Of Stock Option Activity By Exercise Price) (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Outstanding	1,704,042	1,711,430
Options Outstanding, Weighted Avg. Remaining Contractual Life	'4 years 9 months 15 days	'
Options Outstanding, Weighted Avg. Exercise Price	$1.35	$1.43
Options Exercisable	1,404,473	'
Options Exercisable, Weighted Avg. Exercise Price	$1.50	'
$0.00 to $2.43 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Outstanding, Exercise price minimum	$0	'
Options Outstanding, Exercise price maximum	$2.43	'
Options Outstanding	1,631,542	'
Options Outstanding, Weighted Avg. Remaining Contractual Life	'4 years 10 months 24 days	'
Options Outstanding, Weighted Avg. Exercise Price	$1.21	'
Options Exercisable	1,331,973	'
Options Exercisable, Weighted Avg. Exercise Price	$1.34	'
$2.44 to $4.86 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Outstanding, Exercise price minimum	$2.44	'
Options Outstanding, Exercise price maximum	$4.86	'
Options Outstanding	57,500	'
Options Outstanding, Weighted Avg. Remaining Contractual Life	'2 years 1 month 6 days	'
Options Outstanding, Weighted Avg. Exercise Price	$3.20	'
Options Exercisable	57,500	'
Options Exercisable, Weighted Avg. Exercise Price	$3.20	'
$4.87 to $7.29 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Outstanding, Exercise price minimum	$4.87	'
Options Outstanding, Exercise price maximum	$7.29	'
Options Outstanding	7,500	'
Options Outstanding, Weighted Avg. Remaining Contractual Life	'1 year	'
Options Outstanding, Weighted Avg. Exercise Price	$5.47	'
Options Exercisable	7,500	'
Options Exercisable, Weighted Avg. Exercise Price	$5.47	'
$7.30 to $14.58 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Outstanding, Exercise price minimum	$7.30	'
Options Outstanding, Exercise price maximum	$14.58	'
Options Outstanding	7,500	'
Options Outstanding, Weighted Avg. Remaining Contractual Life	'1 month 6 days	'
Options Outstanding, Weighted Avg. Exercise Price	$12.23	'
Options Exercisable	7,500	'
Options Exercisable, Weighted Avg. Exercise Price	$12.23	'

Stock_Options_And_Restricted_S5

Stock Options And Restricted Stock Awards (Summary Of Stock Option Activity) (Details) (USD $)	12 Months Ended
	Jun. 30, 2014
Stock Options And Restricted Stock Awards [Abstract]	'
Outstanding at July 1, 2013, Number of Options	1,711,430
Options granted, Number of Options	191,500
Options forfeited, Number of Options	-88,063
Options expired, Number of Options	-110,825
Options exercised, Number of Options	0
Outstanding at June 30, 2014, Number of Options	1,704,042
Exercisable at June 30, 2014, Number of Options	1,404,473
Outstanding at July 1, 2013, Weighted-avg. Exercise Price Per Option	$1.43
Options granted, Weighted-avg. Exercise Price Per Option	$0.38
Options forfeited, Weighted-avg. Exercise Price Per Option	$0.66
Options expired, Weighted-avg. Exercise Price Per Option	$1.49
Outstanding at June 30, 2014, Weighted-avg. Exercise Price Per Option	$1.35
Exercisable at June 30, 2014, Weighted-avg. Exercise Price Per Option	$1.50
Outstanding at June 30, 2014, Weighted-avg. Remaining Contractual Term	'4 years 9 months 15 days
Exercisable at June 30, 2014, Weighted-avg. Remaining Contractual Term	'4 years 7 days

Stock_Options_And_Restricted_S6

Stock Options And Restricted Stock Awards (Summary Of Non-Vested Options) (Details) (USD $)	12 Months Ended
	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options granted, Number of Options	191,500
Options forfeited, Number of Options	-88,063
Non-Vested Options [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Nonvested at June 30, 2013, Number of Options	383,115
Options granted, Number of Options	191,500
Options forfeited, Number of Options	-88,063
Options vested, Number of Options	-186,983
Nonvested at June 30, 2014, Number of Options	299,569
Nonvested at June 30, 2013, Weighted-avg. Grant-Date Fair Value	0.46
Shares granted, Weighted-avg. Grant-Date Fair Value	0.21
Shares forfeited, Weighted-avg. Grant-Date Fair Value	0.34
Shares vested, Weighted-avg. Grant-Date Fair Value	0.48
Nonvested at June 30, 2014, Weighted-avg. Grant-Date Fair Value	0.32

Stock_Options_And_Restricted_S7

Stock Options And Restricted Stock Awards (Summary Of Non-Vested Restricted Stock Activity) (Details) (Restricted Non-Vested Options [Member], USD $)	12 Months Ended
	Jun. 30, 2014
Restricted Non-Vested Options [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Non-vested at June 30, 2013, Number of Restricted Stock Awards	113,667
Awards granted, Number of Restricted Stock Awards	377,500
Awards forfeited, Number of Restricted Stock Awards	-35,000
Awards vested, Number of Restricted Stock Awards	-109,865
Non-vested at June 30, 2014, Number of Restricted Stock Awards	346,302
Non-vested at June 30, 2013, Weighted-avg. Grant-Date Fair Value	$0.68
Awards granted, Weighted-avg. Grant-Date Fair Value	$0.28
Awards forfeited, Weighted-avg. Grant-Date Fair Value	$0.38
Awards vested, Weighted-avg. Grant-Date Fair Value	$0.67
Non-vested at June 30, 2014, Weighted-avg. Grant-Date Fair Value	$0.28

Restructuring_Narrative_Detail

Restructuring (Narrative) (Details) (USD $)	0 Months Ended		3 Months Ended	12 Months Ended
	Apr. 10, 2014	Jan. 03, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'
Severance payments	$45,000	$41,000	'	'	'
(Decrease) in cash and cash equivalents	'	'	-98,000	-1,572,000	391,000
Cash utilized for restructuring	'	'	'	86,000	'
Second Restructuring Plan [Member]	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'
Cash utilized for restructuring	'	'	80,000	'	'
Cost Of Goods Sold [Member]	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'
Severance payments	'	'	'	26,000	'
Operating Expense [Member]	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'
Severance payments	'	'	'	$60,000	'

Restructuring_Schedule_Of_Rest

Restructuring (Schedule Of Restructuring Activity) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Restructuring [Abstract]	'
Restructuring charges	$86
Payments	($86)

Other_Accrued_Expenses_Details

Other Accrued Expenses (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Other Accrued Expenses [Abstract]	'	'
Sales tax accrual	$79	$126
Other	420	476
Total other accrued expenses	$499	$602

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Valuation Allowance [Line Items]	'	'
Valuation allowance amounts	$31,516,000	$30,176,000
(Increase) Decrease in valuation allowance	-1,340,000	4,087,000
Federal NOL carryforwards	77,534,000	'
Gross unrecognized tax benefits	14,000	'
Net Operating Loss Carryforward From Exercise Of Stock Options [Member]	'	'
Valuation Allowance [Line Items]	'	'
Valuation allowance amounts	541,000	'
Net Operating Loss Carryforward From Exercise OF Stock Options Tax Effected [Member]	'	'
Valuation Allowance [Line Items]	'	'
Valuation allowance amounts	($184,000)	'

Income_Taxes_Schedule_Of_Compo

Income Taxes (Schedule Of Components Of Income Tax Expense (Benefit)) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Income Taxes [Abstract]	'	'
Current state tax expense (benefit)	$20	$13
Total current income tax expense (benefit)	20	13
Deferred federal income tax expense (benefit)	-33	1
Deferred state income tax expense (benefit)	-3	'
Total deferred income tax expense (benefit)	-36	1
Total federal income tax expense (benefit)	-33	1
Total state income tax expense (benefit)	17	13
Income Tax Expense (Benefit), Total	($16)	$14

Income_Taxes_Reconciliation_Of

Income Taxes (Reconciliation Of Statutory Tax Expense (Benefit) To Actual Tax Expense (Benefit)) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Income Taxes [Abstract]	'	'
Federal statutory rate at 34 percent	($2,592)	($1,459)
State taxes, net of federal tax expense (benefit) and state valuation allowance	-231	-128
Nondeductible expenses	34	17
Stock -based compensation	29	55
Adjustments to net operating losses and credits	918	5,562
Adjustments to deferred tax assets	485	'
Other	1	3
Change in valuation allowance	1,340	-4,036
Income Tax Expense (Benefit), Total	($16)	$14
Federal statutory tax rate, percentage	34.00%	'

Income_Taxes_Schedule_Of_Compo1

Income Taxes (Schedule Of Components Of Net Deferred Tax Assets And Liabilities)) (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Income Taxes [Abstract]	'	'
Net operating loss carry forward	$27,861	$27,131
Definite-lived intangibles	2,851	2,414
Alternative minimum tax credit	3	3
Federal and state general business credits	886	865
Non-qualified stock-based compensation	153	536
Property, plant and equipment	80	64
Accrued expenses	582	318
Gross deferred tax assets	32,416	31,331
Amortization of indefinite-lived intangible	'	-36
Contingent consideration on acquisition	-900	-1,155
Gross deferred tax liabilities	-900	-1,191
Net deferred tax assets before valuation allowance	31,516	30,140
Less: valuation allowance	-31,516	-30,176
Total net deferred tax liability	'	($36)

Income_Taxes_Schedule_Of_Expir

Income Taxes (Schedule Of Expiration Dates And Net Operating Loss Carryforwards And Credits) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Operating Loss Carryforwards [Line Items]	'
Net Operating Loss Carryforward	77,534
Net Operating Loss Carryforward Tax Credits	667
June 30, 2015 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net Operating Loss Carryforward Expiration Dates	30-Jun-15
June 30, 2016 - June 30, 2020 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net Operating Loss Carryforward	21,389
June 30, 2021 - June 30, 2025 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net Operating Loss Carryforward	19,481
Net Operating Loss Carryforward Tax Credits	115
June 30, 2026 - June 30, 2034 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net Operating Loss Carryforward	36,664
Net Operating Loss Carryforward Tax Credits	552
Minimum [Member] | June 30, 2016 - June 30, 2020 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net Operating Loss Carryforward Expiration Dates	30-Jun-16
Minimum [Member] | June 30, 2021 - June 30, 2025 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net Operating Loss Carryforward Expiration Dates	30-Jun-21
Minimum [Member] | June 30, 2026 - June 30, 2034 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net Operating Loss Carryforward Expiration Dates	30-Jun-26
Maximum [Member] | June 30, 2015 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net Operating Loss Carryforward Expiration Dates	30-Jun-15
Maximum [Member] | June 30, 2016 - June 30, 2020 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net Operating Loss Carryforward Expiration Dates	30-Jun-20
Maximum [Member] | June 30, 2021 - June 30, 2025 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net Operating Loss Carryforward Expiration Dates	30-Jun-25
Maximum [Member] | June 30, 2026 - June 30, 2034 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net Operating Loss Carryforward Expiration Dates	30-Jun-34

Deferred_Income_Details

Deferred Income (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014
			Minimum [Member]	Maximum [Member]
Deferred income	$6,000	$5,000	'	'
Deferred income recognition, contract period	'	'	'12 months	'24 months

Goodwill_Details

Goodwill (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Goodwill [Abstract]	'	'
Goodwill acquired	'	$3,036,000
Impairment of goodwill	$3,036,000	$0

Intangible_Assets_Narrative_De

Intangible Assets (Narrative) (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization, including amortization recorded in cost of goods sold, of intangible assets	$227,000	$274,000
Impairment of long-lived assets	'	160,000
Patents And Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, amortization period, in years	'9 years	'
Developed Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Impairment of long-lived assets	274,000	'
Customer Base [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Impairment of long-lived assets	95,000	'
Intangible assets, amortization period, in years	'9 years	'
Trademarks [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Impairment of long-lived assets	$65,000	'
Intangible assets, amortization period, in years	'16 years	'
EDAP Acquisition [Member] | Customer Base [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, amortization period, in years	'3 months	'

Intangible_Assets_Schedule_Of_

Intangible Assets (Schedule Of Intangible Assets) (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Carrying Value	$4,759	$4,749
Accumulated Amortization	-2,955	-2,728
Impairment	-434	-434
Net Carrying Value	1,370	1,587
Other [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Carrying Value	74	64
Accumulated Amortization	-11	-2
Net Carrying Value	63	62
Prostiva Acquisition [Member] | Patents And Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Carrying Value	1,529	1,529
Accumulated Amortization	-443	-311
Impairment	-274	-274
Net Carrying Value	812	944
Prostiva Acquisition [Member] | Customer Base [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Carrying Value	531	531
Accumulated Amortization	-154	-108
Impairment	-95	-95
Net Carrying Value	282	328
Prostiva Acquisition [Member] | Trademarks [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Carrying Value	325	325
Accumulated Amortization	-53	-37
Impairment	-65	-65
Net Carrying Value	207	223
EDAP Acquisition [Member] | Customer Base [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Carrying Value	2,300	2,300
Accumulated Amortization	-2,294	-2,270
Net Carrying Value	$6	$30

Intangible_Assets_Future_Amort

Intangible Assets (Future Amortization Expense Related To Net Carrying Amount Of Intangible Assets) (Details) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Intangible Assets [Abstract]	'
2015	$205
2016	199
2017	199
2018	198
2019	$196

Financing_Arrangement_Details

Financing Arrangement (Details) (USD $)	Jun. 30, 2014	Jun. 28, 2013
Financing Arrangement [Abstract]	'	'
Promissory note payable	'	$5,300,000
Promissory note, interest rate	6.00%	'

Commitments_And_Contingencies_1

Commitments And Contingencies (Narrative) (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 28, 2013
Concentration Risk [Line Items]	'	'	'
Rent expense related to operating leases	$229,000	$227,000	'
Promissory note payable	'	'	$5,300,000
Supplier Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Percentage of inventory purchased from one vendor	70.00%	'	'

Commitments_And_Contingencies_2

Commitments And Contingencies (Schedule Of Future Minimal Annual Lease Commitments) (Details) (Building And Equipment Leases [Member], USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Building And Equipment Leases [Member]	'
Operating Leased Assets [Line Items]	'
2015	$228
2016	231
2017	32
2018	$5

Commitments_And_Contingencies_3

Commitments And Contingencies (Schedule Of Estimated Prostiva Payments) (Details) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Commitments And Contingencies [Line Items]	'
2015	$2,038
2016	2,038
2017	2,038
2018	2,038
2019	2,038
Annual License Maintenance Fee [Member]	'
Commitments And Contingencies [Line Items]	'
2015	65
2016	65
2017	65
2018	65
2019	65
Royalty Obligations [Member]	'
Commitments And Contingencies [Line Items]	'
2015	650
2016	650
2017	650
2018	650
2019	650
Note Payments, Including Interest [Member]	'
Commitments And Contingencies [Line Items]	'
2015	1,323
2016	1,323
2017	1,323
2018	1,323
2019	$1,323

Gain_On_Demutualization_Detail

Gain On Demutualization (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2013
Gain On Demutualization [Abstract]	'
Demutualization, cash consideration received	$321